Sign up
Pharma Capital

Polynovo signs deal to launch its skin regeneration technology in Israel

Product evaluation is progressing across more than 25 hospitals in the U.S.
a woman touching her face
NovoSorb BTM has U.S. FDA 510(k) approval

Polynovo Ltd (ASX:PNV) has signed a distribution agreement with AMI Medical Technologies in Israel for its NovoSorb™ BTM tissue scaffold used for skin regeneration.

The NovoSorb BTM (Biodegradable Temporising Matrix) is a tissue scaffold that facilitates the regeneration of the skin when it has been lost or damaged through trauma, burns, surgery or wounding.

AMI Medical Technologies is a distributor of medical devices in Israel and has identified NovoSorb BTM as a good fit within its product portfolio.

NovoSorb BTM has U.S. FDA 510(k) approval for surgical wound application, with sales underway in the U.S., New Zealand, Australia and South Africa.

PolyNovo is establishing a solid foundation for future growth with evaluations progressing in more than 25 hospitals in the U.S.

NovoSorb BTM is PolyNovo’s first commercial product and the company is expecting a solid uplift in FY18 sales in multiple countries, particularly in the U.S.

Interestingly, Polynovo’s technology has demonstrated its potential for other applications including hernia, drug elution pellet and other pipeline products.

PolyNovo ended FY2017 with a significant cash balance of $5.5 million.

The company’s share price increased circa 28% during the past three months, closing at $0.275 on Wednesday.

Register here to be notified of future PNV Company articles
View full PNV profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.